News | Cardio-oncology | July 29, 2019

Statins Reduce Stroke, Cardiovascular Risk in Cancer Patients Following Radiation

Cancer patients who took statin medication had a 32 percent reduction in stroke following radiation therapy to the chest, head or neck

Statins Reduce Stroke, Cardiovascular Risk in Cancer Patients Following Radiation

July 29, 2019 — Cancer patients taking cholesterol-lowering statin medication following radiation therapy of the chest, neck or head had significantly reduced risk of suffering a stroke, and possibly other cardiovascular complications, according to new research. The research appeared in Journal of the American Heart Association.

This is the first large study to explore whether statins reduce cardiovascular complications in patients who have radiation therapy for chest, head or neck cancer.

More than half of cancer patients are treated with radiation therapy, which uses high doses of radiation to kill cancer cells and shrink tumors. While radiation treatment has become more precise and long-term survival rates have improved, the radiation can affect nearby healthy cells and cause side effects many years later.

Radiation therapy side effects include scarring or thickening of arteries, and over time that can lead to blockages that cause heart attack and stroke. In fact, the authors point out that cardiovascular disease is the leading cause of illness and death among cancer survivors.

The newly published study looked at whether statin medication, which reduces the formation of plaques that block blood vessels, might lower the risk of cardiovascular and cerebrovascular disease after radiation therapy to the chest, neck or head. The researchers found that the use of statins was associated with a 32 percent reduction in stroke.

There was also a strong trend toward reduction in overall cardiovascular events, such as heart attacks and stroke, and death due to those cardiovascular events. The authors said, however, that the 15 percent reduction they found was not statistically significant due to the high-risk population of patients in the study.

“Statins decrease cholesterol levels and have anti-inflammatory properties. Multiple studies have revealed the beneficial effects of statin therapy on reducing the risks of vascular disease in a variety of populations,” said study author Negar Mousavi, M.D., M.H.Sc., at McGill University Health Center in Montreal, Canada. “Statins are protective in patients with heart disease, previous strokes and with high cholesterol levels.”

For the study, the researchers studied data from 5,718 heart attack and stroke patients over age 65 (with a mean age of 75) at McGill University Health Centre in Montreal, Canada, who had undergone radiation therapy for chest, head or neck cancer from 2000 to 2011. The majority — 4,166 patients — were taking statins. Most of the people in the study had underlying cardiovascular disease.

“Our study demonstrated that statin therapy could be favorable even with the competing risks of cancer and cancer-related mortality in patients who received radiation therapy,” said Mousavi who added, “No other agent is recommended with enough evidence to reduce the risk of vascular events among cancer patients receiving radiation to the head, neck or chest.”

However, the authors point out that there is a need for prospective studies to explore the role of statins after radiation therapy in wider populations and to establish definitive guidelines on the management of radiation-induced vascular disease.

Co-authors are Jacinthe Boulet, M.D.; Jessica Pena, M.D.; Edward A. Hulten, M.D.; Tomas G. Neilan, M.D.; Alice Dragomir, M.D.; Carolyn Freeman, M.D.; Christine Lambert, M.D.; Tarek Hijal, M.D.; Lyne Nadeau, M.D.; and James M. Brophy, M.D. Author disclosures are on the manuscript.

For more information: www.ahajournals.org/journal/jaha

 

Reference

1. Boulet J., Peña J., Hulten E.A., et al. Statin Use and Risk of Vascular Events Among Cancer Patients After Radiotherapy to the Thorax, Head, and Neck. Journal of the American Heart Association, June 19, 2019. https://doi.org/10.1161/JAHA.117.005996

Related Content

Ticagrelor Plus Aspirin Reduces Ischemic Events in Stable Coronary Patients With Diabetes
News | Antiplatelet and Anticoagulation Therapies | September 10, 2019
The combination of ticagrelor and aspirin reduces ischemic events compared with aspirin alone in patients with stable...
Prasugrel Cuts Ischemic Events in Acute Coronary Syndrome Patients
News | Antiplatelet and Anticoagulation Therapies | September 09, 2019
Prasugrel is superior to ticagrelor for reducing ischemic events in patients with acute coronary syndrome and a planned...
Advances in Anticoagulants Expand Options for VTE Prevention, Treatment
News | Antiplatelet and Anticoagulation Therapies | July 26, 2019
A new article published in AACN Advanced Critical Care outlines the traditional anticoagulant therapies familiar to...
Fragmin (dalteparin sodium) injection was cleared by the FDA for use in pediatric patients. It was initially approved by the FDA in 1994 for adults and is a type of heparin.

Fragmin (dalteparin sodium) injection is now cleared by the FDA for use in pediatric patients. It was initially approved by the FDA in 1994 for adults and is a type of heparin.

Technology | Antiplatelet and Anticoagulation Therapies | May 17, 2019
May 17, 2019 — The U.S.
PhaseBio Receives FDA Breakthrough Therapy Designation for Ticagrelor Reversal Agent
Technology | Antiplatelet and Anticoagulation Therapies | April 30, 2019
PhaseBio Pharmaceuticals Inc. announced the U.S. Food and Drug Administration (FDA) has granted Breakthrough Therapy...
People With Heart Disease at Risk When Pharmacies Close
News | Antiplatelet and Anticoagulation Therapies | April 24, 2019
April 24, 2019 — New research from the University of Illinois at Chicago shows that when pharmacies close, people sto
Study Finds Only Six Percent of Patients Taking Statins as Directed
News | Antiplatelet and Anticoagulation Therapies | April 18, 2019
A recent study found patients with atherosclerotic cardiovascular disease cut their risk of a second major adverse...
HonorHealth Research Institute Launches SynIVUS-DAPT Study
News | Antiplatelet and Anticoagulation Therapies | April 16, 2019
HonorHealth Research Institute announced the first patients have been enrolled in the SynIVUS-DAPT Study. The clinical...
Lack of Physician Guidance, Fear of Side Effects Influence Statin Compliance
News | Antiplatelet and Anticoagulation Therapies | April 15, 2019
Despite national guidelines indicating statins can lower risk of heart attack and stroke, many patients who could...
Stopping DAPT After One Month Improved Outcomes in Stent Patients
News | Antiplatelet and Anticoagulation Therapies | March 25, 2019
Patients who stopped taking aspirin one month after receiving a stent in the heart’s arteries but continued taking the...
Overlay Init